[A21-04] Ivacaftor (combination with ivacaftor/tezacaftor/elexacaftor; cystic fibrosis, 12 years and older, F508del mutation, heterozygous) - Addendum to Commission A20-83

Last updated 18.02.2021

Project no.:
A21-04

Commission:
Commission awarded on 12.01.2021 by the Federal Joint Committee (G-BA).

Report type:
Addendum

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Airways and respiratory system

Indication:

Patients with cystic fibrosis aged 12 years and older who are heterozygous for the F508del mutation in the CFTR gene with a minimal function mutation

Result of dossier assessment:

Conclusion of dossier assessment A20-83 unchanged

Note:

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Federal Joint Committee (G-BA)

2021.02.18 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form